EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy

Dayane Schmidt iD, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar, Mariane Cariati Tirapelle, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Dimas Tadeu Covas, Virginia Picanço-Castro

Immunotherapy Advances · 01.01.2022 · 2 (1)

DOI: 10.1093/immadv/ltac003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 03.02.2022. Verfasst von Dayane Schmidt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regional Blood Center of the School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brazilian foundations, São Paulo Research Foundation, CTC Center for Cell-based Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell therapy is an innovative approach that permits numerous possibilities in the field of cancer treatment. CAR-T cells have been successfully used in patients with hematologic relapsed/refractory. However, the need for autologous sources for T cells is still a major drawback. CAR-NK cells have emerged as a promising resource using allogeneic cells that could be established as an off-the-shelf treatment. NK cells can be obtained from various sources, such as peripheral blood (PB), bone marrow, umbilical cord blood (CB), and induced pluripotent stem cells (iPSC), as well as cell lines. Genetic engineering of NK cells to express different CAR constructs for hematological cancers and solid tumors has shown promising preclinical results and they are currently being explored in multiple clinical trials. Several strategies have been employed to improve CAR-NK-cell expansion and cytotoxicity efficiency. In this article, we review the latest achievements and progress made in the field of CAR-NK-cell therapy.

Schlagwörter

Stichwörter der Autor:innen

NK cellscancercell therapychimeric antigen receptorgenetic engineering

Autor:innen und Institutionen

  • Regional Blood Center of the School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
  • Department of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

ORCID-Profile: Dayane Schmidt

Förderung

  • Brazilian foundations
  • São Paulo Research Foundation
  • CTC Center for Cell-based Therapy
  • National Institute of Science and Technology in Stem Cell and Cell Therapy
  • National Council for Scientific and Technological Development

Zitieren

APA

Schmidt, D., Ebrahimabadi, S., Gomes, K. R. S., de Moura Aguiar, G., Cariati Tirapelle, M., Nacasaki Silvestre, R., de Azevedo, J. T. C., Tadeu Covas, D., & Picanço-Castro, V. (2022). Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. Immunotherapy Advances, 2(1). https://doi.org/10.1093/immadv/ltac003

Vancouver

Schmidt D, Ebrahimabadi S, Gomes KRS, de Moura Aguiar G, Cariati Tirapelle M, Nacasaki Silvestre R, et al. Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. Immunotherapy Advances. 2022;2(1). doi:10.1093/immadv/ltac003

BibTeX
@article{Schmidt2022,
  author = {Schmidt, Dayane and Ebrahimabadi, Sima and Gomes, Kauan Ribeiro de Sena and de Moura Aguiar, Graziela and Cariati Tirapelle, Mariane and Nacasaki Silvestre, Renata and de Azevedo, Júlia Teixeira Cottas and Tadeu Covas, Dimas and Picanço-Castro, Virginia},
  title = {Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy},
  journal = {Immunotherapy Advances},
  year = {2022},
  volume = {2},
  number = {1},
  doi = {10.1093/immadv/ltac003}
}
Kostenlos starten →